

Epstein-Barr Virus and Childhood Hodgkin's Disease in Honduras and the United States

By Richard F. Ambinder, Philip J. Browning, Ivette Lorenzana, Brigid G. Leventhal, Humberto Cosenza, Risa B. Mann, Eithne M.E. MacMahon, Rene Medina, Virgilio Cardona, Seymour Grufferman, Andrew Olshan, Arthur Levin, Eskild A. Petersen, William Blattner, and Paul H. Levine

In industrialized populations, Hodgkin's disease (HD) has an initial peak in young adulthood, whereas in economically developing populations the initial peak occurs in childhood. This pattern resembles that of infection with poliovirus and suggests an infectious cofactor in the etiology. Serologic studies have linked Epstein-Barr virus (EBV) to young adult and adult HD, and viral nucleic acids and antigens have been detected in a subset of Hodgkin's tumor specimens. To investigate the association of childhood HD with EBV we studied tumor specimens from 11 children treated in Honduras and 25 children treated in the United States using in situ hybridization and antigen detection techniques.

PECULIARITIES in the epidemiology of Hodgkin's disease (HD) suggest that HD, like paralytic polio in the prevaccine era, might be associated with delayed infection by a widespread agent ("the polio model").¹⁻³ Support for this hypothesis has come from observations that in industrialized populations HD has an initial peak in young adulthood, whereas in economically developing populations the initial peak occurs in childhood.⁴

Since 1970,⁵⁻⁷ serologic studies have linked Epstein-Barr virus (EBV) to HD. In most populations, primary EBV infection is asymptomatic. However, in economically advanced populations, in which viral exposure is delayed until early adulthood, primary infection is frequently associated with the syndrome of infectious mononucleosis. There is a consistent finding of increased risk of HD among persons diagnosed with infectious mononucleosis.⁸⁻¹⁴ Furthermore, in patients with a diagnosis of HD, increased antibody titers against EBV antigens antedate diagnosis by several years.¹⁵

Early efforts to detect EBV DNA in HD by DNA-DNA reassociation kinetics failed,¹⁶ leading many investigators to search for an indirect association. However, with the advent of cloned viral probes and blot hybridization, EBV DNA was

detected in 15% to 25% of mostly adult Hodgkin's tumor specimens from North America, Europe, and Japan.¹⁷⁻²⁰ Analysis of the viral terminal repeats as described by Raab-Traub and Flynn²¹ indicated that the EBV genome was present in a monoclonal proliferation of cells.^{18,19,22} Polymerase chain reaction (PCR) amplification has identified EBV in a larger fraction of adult HD cases.^{20,23-25} In situ hybridization provided direct evidence that the virus was present in the malignant cells in Hodgkin's tumors (Reed-Sternberg cells and their variants).^{19,22,26,27} Most recently, EBV gene expression has been detected in Reed-Sternberg cells, indicating that the viral genome is not merely a silent passenger.^{26,28-32} In all of these studies EBV has been detected most commonly in mixed cellularity HD.

© 1993 by The American Society of Hematology.

detected in 15% to 25% of mostly adult Hodgkin's tumor specimens from North America, Europe, and Japan.¹⁷⁻²⁰ Analysis of the viral terminal repeats as described by Raab-Traub and Flynn²¹ indicated that the EBV genome was present in a monoclonal proliferation of cells.^{18,19,22} Polymerase chain reaction (PCR) amplification has identified EBV in a larger fraction of adult HD cases.^{20,23-25} In situ hybridization provided direct evidence that the virus was present in the malignant cells in Hodgkin's tumors (Reed-Sternberg cells and their variants).^{19,22,26,27} Most recently, EBV gene expression has been detected in Reed-Sternberg cells, indicating that the viral genome is not merely a silent passenger.^{26,28-32} In all of these studies EBV has been detected most commonly in mixed cellularity HD.

Given the paucity of data on childhood HD, we undertook to investigate the potential association with EBV by using recently developed detection techniques applicable to fixed specimens. Specimens from patients in Honduras (11 children) and the United States (25 children) were studied.

MATERIALS AND METHODS

Patients and tissues. Formalin- or B5-fixed paraffin-embedded diagnostic biopsy and staging laparotomy specimens (with and without tumor involvement) from 36 children under the age of 15 with HD were studied. The children were treated at the Hospital Escuela (Tegucigalpa, Honduras) or in an institution that is affiliated with a US national collaborative clinical trials group, the Pediatric Oncology Group. The diagnosis was confirmed by a hematopathologist (R.B.M.) after review of hematoxylin and eosin-stained sections in accord with standard criteria.

The in situ hybridization method has been described previously.^{34,35} Digoxigenin-labeled riboprobes were prepared by in vitro transcription of linearized recombinant plasmids in the presence of digoxigenin-UTP (Boehringer Mannheim, Indianapolis, IN). The plasmid, RA386, contains the entire Epstein-Barr early RNA 1 (EBER1) sequence (amplified from B95-8 strain EBV by PCR) subcloned into BlueScript M13 (Stratagene, La Jolla, CA) between T7 and T3 polymerase promoters such that T7 generates sense and T3 generates antisense transcripts. A human cytomegalovirus (CMV) riboprobe was selected as a control because CMV is a widespread herpesvirus that has not been implicated in the pathogenesis of HD.⁷ The plasmid, TCMP10, contains human CMV immediate early 1 exon-4 sequences in a similar vector, as previously described.³⁶ Cells from the two EBV-transformed B-cell lines (B95-8 and Namalwa) and an EBV-negative B-cell lym-

From the Departments of Oncology, Pathology, and Medicine, Johns Hopkins School of Medicine, Baltimore, MD; the National Cancer Institute, Bethesda, MD; the Department of Microbiology, Universidad Nacional Autonoma de Honduras, Tegucigalpa, Honduras; the Department of Pathology, Hospital Escuela, Tegucigalpa, Honduras; the Department of Clinical Epidemiology and Preventive Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA; the Research Triangle Institute Unit, Harrow, Middlesex, UK; the University of Arizona, Tucson, AZ; and the Pediatric Oncology Group, St Louis, MO.

Submitted April 27, 1992; accepted August 31, 1992.

Supported by American Cancer Society Grant No. PDT405 (R.F.A.), National Institutes of Health (NIH) Grant No. RO1 CA47473 (S.G.), the Hodson Trust (R.F.A.), and NIH Grant No. U10 CA-28476 (P.O.G.).

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1993 by The American Society of Hematology.

0006-4971/93/8102-0032\$3.00/0

phoma line (BJAB) were fixed in buffered formalin, embedded in paraffin, and used as positive and negative controls for in situ hybridization experiments.

For LMP-1 detection, tissue culture supernatant containing the mouse monoclonal antibody S12 was used.³⁷ Dewaxed sections were digested in 0.1% trypsin (GIBCO, Grand Island, NY) in 50 mmol/L Tris, pH 7.6, 0.1% CaCl₂ for 10 minutes at room temperature. LMP-1 was detected by a standard immunoperoxidase technique (Vectastain Elite ABC; Vector, Burlingame, CA).³³ Blocking agent consisted of 2% normal horse serum in phosphate-buffered saline (PBS) with 0.5% dried milk. S12 primary antibody and biotinylated horse antimouse secondary antibody (Vector) were used at dilutions of 1:2 and 1:200 in blocking agent, respectively. Slides were counterstained with hematoxylin.

For strain typing virus only formalin-fixed specimens could be studied. Sections (5 µm) were cut from tissue blocks and placed in microtubes. The microtome blade was changed between specimens to avoid carryover. Sections were deparaffinized with xylene, digested with proteinase K, extracted with phenol and chloroform, ethanol precipitated, and resuspended in PCR amplification buffer as previously described.³⁸ Amplification of a strain-variable region of the Epstein-Barr nuclear antigen 2 coding sequence (EBNA-2) and Southern blot hybridization of the amplification products with type-specific probes was performed as described by Sixbey et al.³⁹ DNA from the Raji and AG876 African Burkitt's lymphoma cell lines that carry EBV type A and type B, respectively, were used as positive controls. Human placental DNA was used as a negative control.

RESULTS

HD tumor specimens from 11 children treated in Honduras and 25 children treated at Pediatric Oncology Group-affiliated institutions in the United States were studied. The characteristics of the children studied are presented in Table 1. The mean age at diagnosis was 8 years among the Honduran patients and 10 years among the United States' patients studied. Mixed cellularity and nodular sclerosis were the most common subtypes in the Honduran and United States' patients, respectively. The distribution of histologies in childhood HD in the United States is similar to that reported from the Pediatric Oncology Group previously, with mixed cellularity representing about one-third of the disease in children less than 10 years but only about 15% in patients aged 11 to 15 years.⁴⁰ The male to female ratios were close to unity in both countries.

Tumor specimens from all of the Honduran patients showed intense hybridization with the EBV EBER1 antisense probe (Fig 1 and Table 1). These patients' tumors included six with mixed cellularity histology, three with nodular sclerosis histology, one with lymphocyte predominant histology, and one that was interfollicular and therefore not subclassified (Fig 2). Only 9 of 25 United States' patients were hybridization positive. These tumors included six of seven with mixed cellularity histology, 2 of 15 with nodular sclerosis histology, neither of two with lymphocyte predominant histology, and one that was interfollicular. The hybridization signal was clumped with margination against the nuclear membrane and nucleolus, and was predominantly associated with Reed-Sternberg cells and their variants (Fig 1). EBER-positive cells of the size of small lymphocytes were also detected in nine cases with EBV-positive Reed-Sternberg cells. Small EBER-positive cells were not detected in any of the specimens in

Table 1. Characteristics of Children With HD and Reed-Sternberg Hybridization Results

	EBV Honduras		EBV United States	
	+	-	+	-
No. of patients	11	0	9	16
Age ≤9 yr	8	0	4	3
Age 10-14 yr	3	0	5	13
Male	6	0	6	6
Female	5	0	3	10
Race				
White			4	10
Black			1	4
Hispanic			3	1
Other			1	1
Histologic subtype				
Mixed cellularity	6	0	6	1
Nodular sclerosis	3	0	2	13
Lymphocyte predominant	1	0	0	2
Interfollicular	1	0	1	0

which large malignant cells were not EBER positive. In some cases, the intensity of hybridization was so strong as to obscure the nuclear morphology.

Hybridization with EBER1 sense probe, complementary only to DNA, did not lead to hybridization signal in any specimen. The failure of the sense probe to hybridize to tumor cells is consistent with the interpretation that only RNA, and not DNA, was being detected by the antisense probe. Selective hybridization to RNA was anticipated because of the non-denaturing conditions used. Thus, the sense RNA probe served as a negative control, indicating that Reed-Sternberg cells are not nonspecifically "sticky."

Further investigations were undertaken to better characterize the high EBV association with HD in the Honduran patients. Detection of EBV by in situ hybridization was confirmed in each case by immunoperoxidase detection of the EBV-transforming protein, LMP-1 (Fig 3). This protein was seen to be cytoplasmic and membranous and associated with Reed-Sternberg cells and their variants. In several cases, both techniques were performed in succession on the same tissue section (Fig 3, inset). Lymphoid tissues obtained at diagnostic staging laparotomy from patients with EBV-positive tumor specimens were studied. At least one further tumor specimen was available from five patients. All of these tumor specimens were EBV positive. Ten specimens of lymphoid tissue, from these same patients but uninvolved by tumor, were also available. These were EBV negative. A CMV probe did not lead to hybridization in any specimen. PCR amplification of DNA extracted from formalin-fixed paraffin sections from each of these patients, followed by Southern blot hybridization, detected type A EBV in each tumor specimen. Type B was not detected in any tumor specimen. Two specimens from young adults with nodular sclerosis HD were also studied and these were EBV negative.

DISCUSSION

Although a link between childhood HD in underdeveloped countries and EBV has been hypothesized,⁴¹ direct detection




Fig 1. Hybridization with EBER1 antisense probe. A biopsy section of mixed cellularity HD was hybridized with EBER1 antisense probe and counterstained with eosin. (Left) Intense hybridization is seen over numerous neoplastic cells and occasional small cells. (Right) Hybridization signal is clumped and margined against the nuclear membrane and nucleolus of a Reed-Sternberg cell. The nucleolus and areas of nucleoplasm are devoid of signal.




Fig 2. Bar graph showing the relationship between histologic subtype, country, and EBV association. MC, mixed cellularity; Other, nodular sclerosis, lymphocyte predominant, interfollicular; US, United States; Hond, Honduras. (■) EBV positive; (□) EBV-negative.




Fig 3. LMP-immunoperoxidase staining. A biopsy section of mixed cellularity HD shows cytoplasmic and membranous labeling of Reed-Sternberg cells and their variants. The section is counterstained with hematoxylin. (Inset) Combined in situ hybridization and antigen detection. EBER1 hybridization signal is nuclear; LMP-immunoperoxidase staining is cytoplasmic.

studies have not been systematically performed in children. Lack of study has, in part, reflected a lack of tumor tissue. The initial studies detecting EBV in adult HD all relied on Southern blot hybridization of DNA extracted from snap-frozen or fresh tumor tissue—a detection method not readily applicable to a rare disease. The techniques applied here have been optimized for application to routinely fixed tissue. In situ hybridization studies with the EBV large internal repeat probe using ³⁵S label was the method initially used to identify the cellular locus of EBV in HD and is applicable to formalin-fixed paraffin-embedded material, but appears to be less sensitive and to be associated with more background.^{19,22,26} The intensity of the hybridization signal here and the absence of background are attributable to the very high copy number of the EBER transcripts in infected cells and their resistance to autolysis. Whereas most of the EBV genome is either expressed at very low copy numbers (10 to 100 copies per cell) or not expressed at all during latent infection, the EBV EBER1 and 2 RNAs are expressed in great abundance (up to 10⁷ copies per cell).^{42,43} Thus, the technique is sufficiently sensitive to consistently detect EBV in formalin-fixed paraffin-embedded Namalwa cells, a Burkitt's cell line with only two copies of the EBV genome per cell, used as a positive control in these experiments. The EBERs are complexed with cellular proteins and exhibit extensive intramolecular base pairing.^{44,45} These characteristics may account for their stability even in specimens stored at room temperature without fixation for 24 hours and in autopsy specimens.³⁵ The EBERs do not cross-hybridize with other viruses, including human immunodeficiency virus (HIV), CMV, and herpes simplex viruses, or with normal tissues under the conditions used in the assay described.³⁵

The finding that multiple tumor specimens from the same patient were consistent in terms of EBV detection supports the hypothesis that EBV plays a role in tumorigenesis. Furthermore, the absence of detectable viral transcripts in uninvolved lymphoid specimens suggests that virus is largely confined to tumor cells in lymphoid tissues.

The significance of the population of EBV-positive cells the size of small lymphocytes is uncertain. The existence of this population of cells, not noted in studies using the EBV large internal repeat probe,^{19,22,31} was only recognized with the increased sensitivity achieved by targeting the abundant EBER transcripts.^{30,32} We have detected such cells in lymph nodes from patients with infectious mononucleosis, in lymphoid tissue from HIV-infected patients, and in patients with congenital immunodeficiencies. In this series, these small EBER-positive cells were detected only in patients who also had EBER-positive Reed-Sternberg cells, and with two exceptions were quite rare. Other investigators have reported detection of these cells in HD tissues in which the Reed-Sternberg cells were EBV negative; we have seen such cases in adults, but not in this series of children. Whether they are related to the disease process or are epiphenomena remains to be determined.

LMP-1 is one of two EBV latency genes that have been associated with cellular growth regulation.⁴⁶ When overexpressed in rodent cells, this protein is transforming.⁴⁷ Recent evidence also suggests that this protein protects against apop-

toxis (programmed cell death), perhaps by increasing expression of the *bcl-2* protooncogene.⁴⁸ Expression of the LMP-1 has been previously reported in adult HD.^{28,29,31} Its detection here in children provides confirmation of the in situ hybridization results and further support for the hypothesis that, when present, EBV is not merely a silent passenger in HD, but is contributing directly to its pathogenesis. Interestingly, this protein is not expressed in endemic (African) Burkitt's lymphoma.⁴⁹ Thus, it is reasonable to suppose that the role of EBV is likely to be very different in EBV-associated HD and EBV-associated Burkitt's lymphoma.

Mixed cellularity HD in children in Honduras and the United States was strongly associated with HD (92%). Other investigators have reported a strong histologic association in series composed largely of adult patients. LMP-1 was detected in 23 of 24 (96%) cases of mixed cellularity HD in a Danish series.²⁸ Other histologies of HD in children in Honduras are also strongly associated with EBV. In contrast, in children in the United States, only a minority of other histologies were EBV associated (Fig 2). Interestingly, one of two cases of EBV-positive nodular sclerosis HD in the United States sample was in a hispanic child and tumors from three of four hispanic children in the United States sample were EBV positive. The numbers studied are too small to allow any firm conclusions to be drawn, but suggest the possibility that the association of EBV with childhood HD may vary as a function of histology, geography, or ethnic background.

Geographic or ethnic variation in the incidence and viral association of malignancies in which EBV has been detected is not a new phenomenon.⁵⁰ Although EBV is a ubiquitous virus, there is geographic variation in the incidence of nasopharyngeal carcinoma and Burkitt's lymphoma. Nasopharyngeal carcinoma is common in Southern Chinese, including those who emigrate, but rare in most of the rest of the world. There appears to be no geographic variation in its apparent 100% association with EBV.^{34,50,51} In contrast, there is geographic variation in the incidence and viral association of Burkitt's lymphoma.⁵² In North America and Europe, Burkitt's lymphoma is a relatively uncommon tumor and is only occasionally associated with EBV, whereas in Equatorial Africa, the tumor is common and is usually associated with the virus.⁵² Evidence has been marshalled to suggest that, despite similar histology and karyotype, EBV-negative and EBV-positive Burkitt's lymphoma may differ in the locus of the chromosomal breakpoints within the *c-myc* gene.⁵²

Age may also be an important determinant in the viral association. In a recent series from Glasgow, Jarrett et al reported that Southern blot hybridization demonstrated EBV DNA in the tumors of 71% of patients with HD aged 50 years or more and 54% of patients with HD aged 14 years and younger, but less than 15% of patients aged 15 to 34 years.⁵⁵

Recently, it has been demonstrated that, much like herpes simplex viruses 1 and 2, EBV is comprised of at least two common strains, A and B. In vitro assays show clear differences between these two strains. The type A strain (prototype B95-8) transforms lymphocytes much more efficiently than the type B strain (prototype AG876), and the lymphocyte transformants containing the type A strain are more easily maintained in culture than transformants carrying the type

B strain.⁵³ Sixbey et al have designed PCR primers for a strain-variable region that he has used to assess EBV type in throat washings, and has reported detection of type B virus in 41% of healthy EBV shedders, type A virus in 50%, and both strains in 9%.³⁹ However, immune function may selectively restrict systemic expression of EBV type B infection. Thus, Sculley et al has reported that type B EBV lymphoblastoid cell lines could be established from the peripheral blood of HIV-infected patients sixfold more frequently than from the peripheral blood of normal controls.⁵⁴ Our previous work has shown that adult HD in the United States is associated almost exclusively with type A EBV (14 of 15 cases studied; Ambinder, unpublished results). Jarrett et al has reported strain typing 30 cases of EBV-associated HD and all were type A.⁵⁵ The present study indicates that in children in Honduras, type A EBV also predominates. It should be noted that the existence of EBV-positive small, possibly reactive lymphocytes makes the interpretation of PCR without correlative *in situ* hybridization hazardous insofar as viral sequences amplified might derive from reactive lymphocytes rather than tumor cells; it is certainly possible that we amplified virus from both subpopulations of cells. However, inasmuch as we identified only a single strain of virus, we are confident of our conclusion that type A EBV was present in the Reed-Sternberg cells in these cases.

The absence of EBV from lymphoid tissues not involved by tumor and the absence of type B EBV in children with EBV-associated HD in Honduras suggests that the association is not a consequence of global immunocompromise, but must represent some more subtle and complex interaction between virus and host.

These findings support the hypothesis that EBV contributes to the pathogenesis of HD in children, particularly in mixed cellularity HD. If geographic, racial, or ethnic variation in the association of EBV with HD is confirmed in other locales, this may serve as a starting point for studies involving other important etiologic cofactors. The techniques of EBER1 RNA and LMP1 protein detection, here applied to conventionally fixed tissues, should facilitate future epidemiologic studies of the viral-tumor association in diverse settings.

ACKNOWLEDGMENTS

We thank the members of the Pediatric Oncology Group Hodgkin's Disease Committee for support and specimens; Dr Jeffrey I. Cohen for anti-LMP-1 monoclonal antibody supernatant; Jian Zhang, Yun Ling and George Pettis for technical assistance; and Linda Heath and Alexandra Morgan for clerical assistance.

REFERENCES

- Newell G: Etiology of multiple sclerosis and Hodgkin's disease. *Am J Epidemiol* 91:119, 1970
- Gutensohn N, Cole P: Epidemiology of Hodgkin's disease in the young. *Int J Cancer* 19:595, 1977
- Gutensohn N, Cole P: Childhood social environment and Hodgkin's disease. *N Engl J Med* 304:135, 1981
- Correa P, O'Connor GT: Epidemiologic patterns of Hodgkin's disease. *Int J Cancer* 8:192, 1971
- Levine PH, Ablashi DV, Berard CW, Carbone PP, Waggoner DE: Elevated antibody titers to herpes-type virus in Hodgkin's disease. *Proc Am Assoc Cancer Res* 11:49, 1970
- Johansson B, Klein G, Henle W, Henle G: Epstein-Barr virus (EBV) associated antibody patterns in malignant lymphoma and leukemia. I. Hodgkin's disease. *Int J Cancer* 6:450, 1970
- Levine PH, Ablashi DV, Berard CW, Carbone PP, Waggoner DE, Malan L: Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. *Cancer* 27:416, 1971
- Evans AS, Gutensohn NM: A population-based case-control study of EBV and other viral antibodies among persons with Hodgkin's disease and their siblings. *Int J Cancer* 34:149, 1984
- Miller RW, Beebe GW: Infectious mononucleosis and the empirical risk of cancer. *J Natl Cancer Inst* 50:315, 1973
- Rosdahl N, Larsen SO, Clemmesen J: Hodgkin's disease in patients with previous infectious mononucleosis: 30 years' experience. *Br Med J* 2:253, 1974
- Kvale G, Hoiby EA, Pedersen E: Hodgkin's disease in patients with previous infectious mononucleosis. *Int J Cancer* 23:593, 1979
- Carter CD, Brown TM Jr, Herbert JT, Heath CW Jr: Cancer incidents following infectious mononucleosis. *Am J Epidemiol* 105:30, 1977
- Munoz N, Davidson RJL, Witthoff B, Ericsson JE, de-The G: Infectious mononucleosis and Hodgkin's disease. *Int J Cancer* 22:1, 1978
- Connelly RR, Christine BW: A cohort study of cancer following infectious mononucleosis. *Cancer Res* 34:1172, 1974
- Mueller N, Evans A, Harris N, Comstock G, Jellum E, Magnus K, Orentreich N, Polk F, Vogelmann J: Hodgkin's disease and Epstein-Barr virus. *N Engl J Med* 320:689, 1989
- Nonoyama M, Kawai Y, Huang CH, Pagano JS, Hirshaut Y, Levine PH: Epstein-Barr virus DNA in Hodgkin's disease, American Burkitt's lymphoma, and other human tumors. *Cancer Res* 34:1228, 1974
- Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J: Epstein-Barr viral DNA in tissues of Hodgkin's disease. *Am J Pathol* 129:86, 1987
- Staal SP, Ambinder R, Beschoner WE, Hayward GS, Mann R: A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin's disease. *Am J Clin Pathol* 91:1, 1989
- Anagnostopoulos I, Herbst H, Niedobitek G, Stein H: Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1 positive anaplastic large cell lymphoma by combined Southern blot and *in situ* hybridization. *Blood* 74:810, 1989
- Ohshima K, Kikuchi M, Eguchi F, Masuda Y, Sumiyoshi Y, Mohtai H, Takeshita M, Kimura N: Analysis of Epstein-Barr viral genomes in lymphoid malignancy using Southern blotting, polymerase chain reaction and *in situ* hybridization. *Virchows Arch [B]* 59:383, 1990
- Raab-Traub N, Flynn K: The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. *Cell* 47:883, 1986
- Weiss LM, Movahed LA, Warnke RA, Sklar J: Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. *N Engl J Med* 320:502, 1989
- Uhara H, Sasto Y, Mukai K, Askao I, Matsuno Y, Furuya S, Hoshikawa T, Shimamoto Y, Saida T: Detection of Epstein-Barr virus DNA in Reed-Sternberg cells of Hodgkin's disease using the polymerase chain reaction and *in situ* hybridization. *Jpn J Cancer Res* 81:272, 1990
- Herbst H, Niedobitek G, Kneba M, Hummel M, Finn T, Anagnostopoulos I, Bergholz M, Krieger G, Stein H: High incidence of Epstein-Barr virus genomes in Hodgkin's disease. *Am J Pathol* 137:13, 1990
- Ambinder RF, Wu T-C, Lambe B, Zhang J, Charache P, Zehnbauser BA, Hayward GS, Mann RB: Absence of EBV in Reed-Sternberg cells in many cases of Hodgkin's disease, in Ablashi DV

- (ed): Epstein-Barr Virus and Human Disease. Clifton Heights, NJ, Humana, 1991, p 277
26. Wu T-C, Mann RB, Charache P, Hayward SD, Staal S, Lambe BC, Ambinder RF: Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. *Int J Cancer* 46:801, 1990
 27. Brousset P, Chittal S, Schlaifer D, Icart J, Payen C, Rigal-Huguet F, Voigt J-J, Delsol G: Detection of Epstein-Barr virus messenger RNA in Reed-Sternberg cells of Hodgkin's disease by *in situ* hybridization with biotinylated probes on specially processed modified acetone methyl benzoate xylene (ModAMeX) sections. *Blood* 77:1781, 1991
 28. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS: Expression of Epstein-Barr virus (EBV) latent gene products in tumour cells of Hodgkin's disease. *Lancet* 337:320, 1991
 29. Herbst H, Dallenbach F, Hummel M, Niedobitek G, Pileri S, Muller-Lantzsch N, Stein H: Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. *Proc Natl Acad Sci USA* 88:4766, 1991
 30. Weiss LM, Chen YY, Liu XF, Shibata D: Epstein-Barr virus and Hodgkin's disease. A correlative *in situ* hybridization and polymerase chain reaction study. *Am J Pathol* 139:1259, 1991
 31. Delsol G, Brousset P, Chittal S, Rigal-Huguet F: Correlation of the expression of Epstein-Barr virus latent membrane protein and *in situ* hybridization with biotinylated BamH1-W probes in Hodgkin's disease. *Am J Pathol* 140:247, 1992
 32. Herbst H, Steinbrecher E, Niedobitek G, Young LS, Brooks L, Müller-Lantzsch N, Stein H: Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. *Blood* 80:484, 1992
 33. Cartun RW, Pedersen CA: An immunocytochemical technique offering increased sensitivity and a lowered cost with a streptavidin horseradish-peroxidase conjugate. *J Histotech* 12:273, 1989
 34. Wu T-C, Mann RB, Epstein J, MacMahon E, Lee WA, Charache P, Hayward SD, Kurman RJ, Hayward GS, Ambinder RF: Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma: A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. *Am J Pathol* 138:1461, 1991
 35. MacMahon EME, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, McArthur JC, Ambinder RF: Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. *Lancet* 338:969, 1991
 36. Wu T-C, Hruban RH, Ambinder RF, Pizzorno M, Cameron DE, Baumgartner WA, Reitz BA, Hayward GS, Hutchins GM: Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts. *Am J Pathol* 140:739, 1992
 37. Mann KP, Thorley-Lawson D: Posttranslational processing of the Epstein-Barr virus-encoded p63/LMP protein. *J Virol* 61:2100, 1987
 38. Ambinder RF, Lambe BC, Mann RB, Hayward SD, Zehnbauser BA, Burns WS, Charache P: Oligonucleotides for polymerase chain reaction amplification and hybridization detection of Epstein-Barr virus DNA in clinical specimens. *Mol Cell Probes* 4:397, 1990
 39. Sixbey JW, Chesney PJ, Resnick L, Shirley P, Buntin DM: Detection of a second widespread strain of Epstein-Barr virus. *Lancet* 2:761, 1989
 40. Leventhal BG, Donaldson SS: Hodgkin's disease, in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology. Philadelphia, PA, Lippincott, 1989, p 457
 41. Evans AS, Kirchoff LV, Pannijti CS, Carvalho RPS, McClelland KE: A case-control study of Hodgkin's disease in Brazil. II. Seroepidemiologic studies in cases and family members. *Am J Epidemiol* 112:609, 1980
 42. Howe JG, Steitz JA: Localization of Epstein-Barr virus-encoded small RNAs by *in situ* hybridization. *Proc Natl Acad Sci USA* 83:9006, 1986
 43. Lerner MR, Andrews NC, Miller G, Steitz JA: Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. *Proc Natl Acad Sci USA* 78:805, 1981
 44. Glickman JN, Howe JG, Steitz JA: Structural analyses of EBER1 and EBER2 ribonucleoprotein particles present in Epstein-Barr virus-infected cells. *J Virol* 62:902, 1988
 45. Toczyski DP, Steitz JA: EAP, a highly conserved cellular protein associated with Epstein-Barr virus small RNAs (EBERs). *EMBO J* 10:459, 1991
 46. Kieff E, Liebowitz D: Epstein-Barr virus and its replication, in Fields BN, Knipe DM (eds): Virology (ed 2). New York, NY, Raven, 1990, p 1889
 47. Wang D, Liebowitz D, Kieff E: An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. *Cell* 43:831, 1985
 48. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A: Induction of *bcl-2* expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. *Cell* 65:1107, 1991
 49. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupan H, Rickinson AB: Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. *EMBO J* 6:2743, 1987
 50. Miller G: Epstein-Barr virus. Biology, pathogenesis, and medical aspects, in Fields BN, Knipe DM (eds): Virology (ed 2). New York, NY, Raven, 1990, p 1921
 51. Raab-Traub N, Flynn K, Pearson G, Huang A, Levine P, Lanier A, Pagano J: The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. *Int J Cancer* 39:25, 1987
 52. Shiramizu B, Barriga F, Neequaye J, Jafri A, Dalla-Favera R, Neri A, Gutierrez M, Levine P, Magrath I: Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: Relevance to geography and Epstein-Barr virus association. *Blood* 77:1516, 1991
 53. Zimmer U, Aldinger HK, Lenoir GM, Vuillaume M, Knebel-Doerberitz MV, Laux G, Desgranges C, Wittmann P, Freese UK, Schneider U, Freese U-K, Bornkamm GW: Geographical prevalence of two types of Epstein-Barr virus. *Virology* 154:56, 1986
 54. Sculley TB, Apolloni A, Hurren L, Moss DJ, Cooper DA: Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. *J Infect Dis* 162:643, 1990
 55. Jarrett RF, Gallagher A, Jones DB, Alexander FE, Krajewski AS, Kelsey A, Adams J, Angus B, Gledhill S, Wright DH, Cartwright RA, Onions DE: Detection of Epstein-Barr virus genomes in Hodgkin's disease: Relation to age. *J Clin Pathol* 44:844, 1991